刚刚！天境生物与之科控股达成超长效创新药合作

Core Insights - Tianjing Biopharma has signed a collaboration agreement with Zhijiang Laboratory Technology Holdings to develop next-generation long-acting innovative biologics, including growth hormones, aimed at providing more convenient treatment options for patients [1][5]. Company Overview: Tianjing Biopharma - Tianjing Biopharma focuses on innovative therapies for autoimmune diseases, tumor immunology, and metabolic diseases, with a differentiated dual-tier innovative drug pipeline [6]. - The first tier includes three products (Fizetuzumab, Eitan Growth Hormone α, and Idaglutide α) that have entered the product listing acceptance stage, while four additional innovative products are in the registration clinical stage or about to start Phase III clinical trials [6]. - The second tier consists of First-in-Class innovative drug projects based on the AntibodyPLUS platform, which are about to enter Phase I clinical trials or initiate clinical applications [6][7]. - The company is accelerating the internationalization of its innovative drug pipeline and integrating R&D, production, and product listing processes in China through collaborations with partners like Jichuan Pharmaceutical, Shiyao Group, and Sanofi [7]. Company Overview: Zhijiang Laboratory Technology Holdings - Zhijiang Laboratory Technology Holdings was established on September 27, 2020, to accelerate the application of technological achievements in the field of intelligent computing and to serve the development of the digital economy and emerging industries [8]. - The company has a registered capital of 100 million yuan and is located in the Future Technology City AI Town in Yuhang District, Hangzhou [8]. - Zhijiang Holdings is dedicated to providing high-quality full-chain services for the transformation and industrialization of technological achievements, including basic services like policy promotion and project due diligence, as well as value-added services such as concept verification and financing [8]. Collaboration Insights - The collaboration will leverage Zhijiang Laboratory's AI-driven research discovery platform, BioDeepDiscovery (BDD), while Tianjing Biopharma will contribute its extensive R&D experience, biological data, and preclinical research capabilities [2][6]. - The partnership aims to combine the strengths of both companies to accelerate drug development processes, particularly in exploring long-acting innovative biologics across multiple therapeutic areas [2][6].